Loading...
Kiniksa Pharmaceuticals, Ltd.
KNSA•NASDAQ
Healthcare
Biotechnology
$30.06
$-0.31(-1.02%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Financial Performance & Income Statement Overview
Review Kiniksa Pharmaceuticals, Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
56.60%
↑ 56.60%
Operating Income Growth
-81.04%
↓ 81.04%
Net Income Growth
-406.68%
↓ 406.68%
Operating Cash Flow Growth
93.14%
↑ 93.14%
Operating Margin
0.85%
↑ 0.85%
Gross Margin
77.35%
↑ 77.35%
Net Profit Margin
0.90%
↑ 0.90%
ROE
1.05%
↑ 1.05%
ROIC
0.82%
↑ 0.82%
Kiniksa Pharmaceuticals, Ltd. (KNSA) Income Statement & Financial Overview
Review Kiniksa Pharmaceuticals, Ltd.'s (KNSA) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $137.78M | $122.54M | $112.21M | $108.63M |
| Cost of Revenue | $61.66M | -$62.23M | $49.42M | $42.45M |
| Gross Profit | $76.13M | $184.76M | $62.80M | $66.18M |
| Gross Profit Ratio | $0.55 | $1.51 | $0.56 | $0.61 |
| R&D Expenses | $19.32M | $35.22M | $26.06M | $23.90M |
| SG&A Expenses | $43.53M | $40.53M | $46.40M | $42.40M |
| Operating Expenses | $62.85M | $204.06M | $72.46M | $66.29M |
| Total Costs & Expenses | $124.51M | $141.84M | $121.87M | $108.75M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $400000.00 | $399000.00 | $430000.00 |
| EBITDA | $13.27M | -$18.90M | -$9.66M | $313000.00 |
| EBITDA Ratio | $0.10 | -$0.15 | -$0.09 | $0.003 |
| Operating Income | $13.27M | -$19.30M | -$9.66M | -$117000.00 |
| Operating Income Ratio | $0.10 | -$0.16 | -$0.09 | -$0.001 |
| Other Income/Expenses (Net) | $2.29M | $2.32M | $2.46M | $2.42M |
| Income Before Tax | $15.56M | -$16.98M | -$7.20M | $2.30M |
| Income Before Tax Ratio | $0.11 | -$0.14 | -$0.06 | $0.02 |
| Income Tax Expense | $7.03M | -$8.09M | $5.49M | $6.21M |
| Net Income | $8.54M | -$8.89M | -$12.69M | -$3.91M |
| Net Income Ratio | $0.06 | -$0.07 | -$0.11 | -$0.04 |
| EPS | $0.12 | -$0.12 | -$0.18 | -$0.06 |
| Diluted EPS | $0.11 | -$0.12 | -$0.18 | -$0.06 |
| Weighted Avg Shares Outstanding | $72.65M | $71.42M | $71.73M | $71.005M |
| Weighted Avg Shares Outstanding (Diluted) | $76.15M | $71.42M | $71.73M | $71.005M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan